The shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC) has been pegged with a rating of Hold by Deutsche Bank in its latest research note that was published on January 3rd, 2019. The research company has also assigned a $27 price target. Deutsche Bank wasn’t the only research firm that published a report of Acadia Healthcare Company, Inc., with other equities research analysts also giving their opinion on the stock. UBS advised investors in its research note published on November 16th, 2018, to Neutral the ACHC stock while also putting a $39 price target. The stock had earned Outperform rating from Wells Fargo when it published its report on January 30th, 2018. The stock was given Neutral rating by Credit Suisse in its report released on November 3rd, 2017. Robert W. Baird was of a view that ACHC is Neutral in its latest report on October 25th, 2017 while giving it a price target of $38. Deutsche Bank thinks that ACHC is worth Hold rating. This was contained in the firm’s report on October 25th, 2017 in which the stock’s price target was also moved to $37.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 8 believe it has the potential for further growth, thus rating it as Hold while 7 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $40.29. The price of the stock the last time has raised by 19.61% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 47.93.
The shares of the company added by 1.26% during the trading session on Friday, reaching a low of $27.81 while ending the day at $29.03. During the trading session, a total of 2.2 million shares were traded which represents a 26% incline from the average session volume which is 2.97M shares. ACHC had ended its last session trading at 28.67. Acadia Healthcare Company, Inc. currently has a market cap of $2.53B, while its P/E ratio stands at 13.02, while its P/E earnings growth sits at 0.85, with a beta of 0.66. Acadia Healthcare Company, Inc. debt-to-equity ratio currently stands at 1.20, while its quick ratio hovers at 1.20. ACHC 52-week low price stands at $24.27 while its 52-week high price is $45.35.
The company in its last quarterly report recorded $0.55 earnings per share which is below the $0.64 predicted by most analysts. The Acadia Healthcare Company, Inc. generated $760.92 million in revenue during the last quarter, which is slightly lower than the $761.11 million predicted by analysts. In the second quarter last year, the firm recorded $0.70 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -27.27%. Acadia Healthcare Company, Inc. has the potential to record 2.23 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Buckingham Research published a research note on January 11th, 2019 where it informed investors and clients that KB Home (NYSE:KBH) is now rated as Neutral. UBS also rated KBH as Initiated on November 16th, 2018, with its price target of suggesting that KBH could surge by 8.2% from its current share price. Even though the stock has been trading at $21.00/share, analysts expect it to surge higher by 0.81% to reach $23.06/share. It started the day trading at $21.68 and traded between $20.72 and $21.17 throughout the trading session.
A look at its technical shows that KBH’s 50-day SMA is 20.28 while its 200-day SMA stands at 24.08. The stock has a high of $38.80 for the year while the low is $16.82. The company’s P/E ratio currently sits at 7.19, while the P/B ratio is 0.92. The company’s average trading volume currently stands at 2.19M shares, which means that the short-interest ratio is just 2.44 days. Over the past seven days, the company moved, with its shift of 2.47%. Looking further, the stock has dropped -2.08% over the past 90 days while it lost -21.53% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. BlackRock Fund Advisors bought more KBH shares, increasing its portfolio by +0.03% during the last quarter. This move now sees BlackRock Fund Advisors purchasing 2,486 shares in the last quarter, thus it now holds 9,587,141 shares of KBH, with a total valuation of $183,114,393. The Vanguard Group Inc meanwhile bought more KBH shares in the recently filed quarter, changing its stake to $151,696,173 worth of shares. AQR Capital Management LLC followed the path by decreasing its KBH portfolio by -0.40% in the quarter. This means that AQR Capital Management LLC sold -17,154 shares in the last quarter and now controls 4,304,081 shares of the KBH stock, with the valuation hitting $82,207,947.
Similarly, JPMorgan Investment Management I increased its KB Home shares by +28.00% during the recently filed quarter. After buying 637,192 shares in the last quarter, the firm now controls 2,912,889 shares of KB Home which are valued at $55,636,180. In the same vein, Dimensional Fund Advisors LP increased its KB Home shares by during the most recent reported quarter. The firm bought 63,964 shares during the quarter which increased its stakes to 2,847,786 shares and is now valued at $54,392,713. Following these latest developments, around 1.50% of KB Home stocks are owned by institutional investors and hedge funds.